Published in Antimicrob Agents Chemother on November 01, 1986
Standardization of disk diffusion and agar dilution susceptibility tests for Neisseria gonorrhoeae: interpretive criteria and quality control guidelines for ceftriaxone, penicillin, spectinomycin, and tetracycline. J Clin Microbiol (1989) 2.96
Genetic loci and linkage associations in Neisseria gonorrhoeae and Neisseria meningitidis. Clin Microbiol Rev (1989) 2.35
Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA. Antimicrob Agents Chemother (2007) 2.07
Mutations in ponA, the gene encoding penicillin-binding protein 1, and a novel locus, penC, are required for high-level chromosomally mediated penicillin resistance in Neisseria gonorrhoeae. Antimicrob Agents Chemother (2002) 2.05
Porin-mediated antibiotic resistance in Neisseria gonorrhoeae: ion, solute, and antibiotic permeation through PIB proteins with penB mutations. J Bacteriol (2006) 1.61
Antibiotic resistance in Neisseria gonorrhoeae: origin, evolution, and lessons learned for the future. Ann N Y Acad Sci (2011) 1.57
Genetics of chromosomally mediated intermediate resistance to ceftriaxone and cefixime in Neisseria gonorrhoeae. Antimicrob Agents Chemother (2009) 1.50
Beta-lactamase plasmids and chromosomally mediated antibiotic resistance in pathogenic Neisseria species. Clin Microbiol Rev (1989) 1.49
The penC mutation conferring antibiotic resistance in Neisseria gonorrhoeae arises from a mutation in the PilQ secretin that interferes with multimer stability. Mol Microbiol (2005) 1.41
Various penA mutations together with mtrR, porB and ponA mutations in Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime or ceftriaxone. J Antimicrob Chemother (2010) 1.29
Cloning and characterization of the ponA gene encoding penicillin-binding protein 1 from Neisseria gonorrhoeae and Neisseria meningitidis. J Bacteriol (1997) 1.11
Rapid chemiluminescent nucleic acid assays for detection of TEM-1 beta-lactamase-mediated penicillin resistance in Neisseria gonorrhoeae and other bacteria. J Clin Microbiol (1988) 1.06
Towards an understanding of chromosomally mediated penicillin resistance in Neisseria gonorrhoeae: evidence for a porin-efflux pump collaboration. J Bacteriol (2006) 1.02
Susceptibility to cephalosporins of penicillin-susceptible and penicillin-resistant strains of Neisseria gonorrhoeae from Philadelphia. Antimicrob Agents Chemother (1989) 0.94
Simple, rapid, and inexpensive detection of Neisseria gonorrhoeae resistance mechanisms using heat-denatured isolates and SYBR green-based real-time PCR. Antimicrob Agents Chemother (2009) 0.82
Mutation in a locus linked to penB-nmp causes suppression of the Mtr phenotype of Neisseria gonorrhoeae. Antimicrob Agents Chemother (1988) 0.80
Inheritance of low-level resistance to penicillin, tetracycline, and chloramphenicol in Neisseria gonorrhoeae. J Bacteriol (1975) 5.02
Penicillin-binding proteins of penicillin-susceptible and intrinsically resistant Neisseria gonorrhoeae. Antimicrob Agents Chemother (1980) 4.80
Genetic mapping of linked antibiotic resistance loci in Neisseria gonorrhoeae. J Bacteriol (1974) 4.13
A community-based outbreak of infection with penicillin-resistant Neisseria gonorrhoeae not producing penicillinase (chromosomally mediated resistance). N Engl J Med (1985) 2.85
Chromosomally mediated resistance in Neisseria gonorrhoeae in the United States: results of surveillance and reporting, 1983-1984. J Infect Dis (1986) 2.49
Loss of low-level antibiotic resistance in Neisseria gonorrhoeae due to env mutations. J Bacteriol (1975) 2.43
Specificity of DNA uptake in genetic transformation of gonococci. Biochem Biophys Res Commun (1979) 2.34
Genetic analysis of drug resistance in Neisseria gonorrhoeae: identification and linkage relationships of loci controlling drug resistance. Antimicrob Agents Chemother (1975) 2.05
Properties of penicillin-binding proteins in Neisseria gonorrhoeae. Antimicrob Agents Chemother (1981) 1.72
Genetic analysis of drug resistance in Neisseria gonorrhoeae: production of increased resistance by the combination of two antibiotic resistance loci. J Bacteriol (1975) 1.62
Polygenes and modifier genes for tetracycline and penicillin resistance in Neisseria gonorrhoeae. J Gen Microbiol (1980) 1.43
Competition of beta-lactam antibiotics for the penicillin-binding proteins of Neisseria gonorrhoeae. Antimicrob Agents Chemother (1981) 1.38
Changing trends in gonococcal antibiotic resistance in the United States, 1983-1984. MMWR CDC Surveill Summ (1984) 1.16
Penicillin-binding proteins of penicillin-susceptible and intrinsically resistant Neisseria gonorrhoeae. Antimicrob Agents Chemother (1980) 4.80
Identification of singlet oxygen as the cytotoxic agent in photoinactivation of a murine tumor. Cancer Res (1976) 4.60
How does photodynamic therapy work? Photochem Photobiol (1992) 4.49
Photoradiation therapy for the treatment of malignant tumors. Cancer Res (1978) 4.01
Determination of [3H]- and [14C]hematoporphyrin derivative distribution in malignant and normal tissue. Cancer Res (1979) 2.51
Photosensitizers: therapy and detection of malignant tumors. Photochem Photobiol (1987) 2.50
Substitution of lysine at position 104 or 240 of TEM-1pTZ18R beta-lactamase enhances the effect of serine-164 substitution on hydrolysis or affinity for cephalosporins and the monobactam aztreonam. Biochemistry (1991) 2.49
Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy. Cancer Res (1985) 2.43
Specificity of DNA uptake in genetic transformation of gonococci. Biochem Biophys Res Commun (1979) 2.34
Photodynamic therapy for the treatment of basal cell carcinoma. Arch Dermatol (1992) 2.01
Autoradiographic distribution of hematoporphyrin derivative in normal and tumor tissue of the mouse. Cancer Res (1981) 2.01
Photoradiation therapy. II. Cure of animal tumors with hematoporphyrin and light. J Natl Cancer Inst (1975) 1.72
Association between early inhibition of DNA synthesis and the MICs and MBCs of carboxyquinolone antimicrobial agents for wild-type and mutant [gyrA nfxB(ompF) acrA] Escherichia coli K-12. Antimicrob Agents Chemother (1988) 1.70
Membrane permeability changes associated with DNA gyrase inhibitors in Escherichia coli. Antimicrob Agents Chemother (1985) 1.61
An in vivo quantitative structure-activity relationship for a congeneric series of pyropheophorbide derivatives as photosensitizers for photodynamic therapy. Cancer Res (1997) 1.60
Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levels. Antimicrob Agents Chemother (1989) 1.55
Analysis of Neisseria gonorrhoeae peptidoglycan by reverse-phase, high-pressure liquid chromatography. J Bacteriol (1985) 1.50
Photoradiation in the treatment of recurrent breast carcinoma. J Natl Cancer Inst (1979) 1.50
Distribution and elimination of Photofrin II in mice. Photochem Photobiol (1989) 1.43
Competition of beta-lactam antibiotics for the penicillin-binding proteins of Neisseria gonorrhoeae. Antimicrob Agents Chemother (1981) 1.38
The theory of photodynamic therapy dosimetry: consequences of photo-destruction of sensitizer. Photochem Photobiol (1987) 1.34
Tobramycin uptake in Escherichia coli is driven by either electrical potential or ATP. J Bacteriol (1991) 1.30
Selection and genetic characterization of Streptococcus pneumoniae mutants resistant to the des-F(6) quinolone BMS-284756. Antimicrob Agents Chemother (2001) 1.30
Photoradiation therapy in advanced carcinoma of the trachea and bronchus. Chest (1984) 1.26
Energetics and efficiency of photoinactivation of murine tumor cells containing hematoporphyrin. Cancer Res (1976) 1.22
Studies on the structure of porphyrins contained in Photofrin II. Photochem Photobiol (1987) 1.22
Photodynamic therapy (PDT) of malignant tumors. Crit Rev Oncol Hematol (1984) 1.21
Murine pharmacokinetics and antitumor efficacy of the photodynamic sensitizer 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a. J Photochem Photobiol B (1993) 1.21
Cloning and identification of the Escherichia coli murB DNA sequence, which encodes UDP-N-acetylenolpyruvoylglucosamine reductase. J Bacteriol (1992) 1.20
Alkyl ether analogs of chlorophyll-a derivatives: Part 1. Synthesis, photophysical properties and photodynamic efficacy. Photochem Photobiol (1996) 1.18
Chlorin and porphyrin derivatives as potential photosensitizers in photodynamic therapy. Photochem Photobiol (1991) 1.16
Comparison of cefepime, cefpirome, and cefaclidine binding affinities for penicillin-binding proteins in Escherichia coli K-12 and Pseudomonas aeruginosa SC8329. Antimicrob Agents Chemother (1991) 1.13
Peptidoglycan biosynthesis in Neisseria gonorrhoeae strains sensitive and intrinsically resistant to beta-lactam antibiotics. J Bacteriol (1983) 1.13
Identification and characterization of cell wall-cell division gene clusters in pathogenic gram-positive cocci. J Bacteriol (1997) 1.13
A study of Salmonella contamination in broiler flocks. Poult Sci (1976) 1.12
Involvement of a change in penicillin target and peptidoglycan structure in low-level resistance to beta-lactam antibiotics in Neisseria gonorrhoeae. Antimicrob Agents Chemother (1985) 1.12
Interaction of photodynamic therapy and hyperthermia: tumor response and cell survival studies after treatment of mice in vivo. Cancer Res (1985) 1.11
Subcellular localization patterns and their relationship to photodynamic activity of pyropheophorbide-a derivatives. Photochem Photobiol (1999) 1.06
Efflux in bacteria: what do we really know about it? Expert Opin Investig Drugs (2001) 1.06
Bacteriochlorophyll-a as photosensitizer for photodynamic treatment of transplantable murine tumors. J Photochem Photobiol B (1991) 1.03
Interaction of hyperthermia and photoradiation therapy. Radiat Res (1984) 1.03
Interstitial photoradiation therapy for primary solid tumors in pet cats and dogs. Cancer Res (1981) 1.02
Membrane lysis in Chinese hamster ovary cells treated with hemtoporphyrin derivative plus light. Photochem Photobiol (1982) 1.01
Photodynamic therapy in patients with colorectal cancer. Cancer (1986) 1.01
Intraoperative photodynamic therapy for retroperitoneal sarcomas. Cancer (1988) 1.00
Activated dyes as antitumor agents. J Natl Cancer Inst (1974) 0.99
Operation and intracavitary photodynamic therapy for malignant pleural mesothelioma: a phase II study. Ann Thorac Surg (1994) 0.99
Photoradiation therapy for cutaneous and subcutaneous malignancies. J Invest Dermatol (1981) 0.98
Photodynamic therapy for palliation of locally recurrent breast carcinoma. J Clin Oncol (1987) 0.98
Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy. Invest New Drugs (1999) 0.98
2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH) in a nude rat glioma model: implications for photodynamic therapy. Lasers Surg Med (2001) 0.96
Studies on the mechanism of tumor destruction by photoradiation therapy. Prog Clin Biol Res (1984) 0.96
Photodynamic therapy (PDT) in the treatment of patients with resistant superficial bladder cancer: a long-term experience. J Clin Laser Med Surg (1998) 0.94
Photobleaching of porphyrins used in photodynamic therapy and implications for therapy. Photochem Photobiol (1987) 0.94
Correlation between site II-specific human serum albumin (HSA) binding affinity and murine in vivo photosensitizing efficacy of some Photofrin components. Photochem Photobiol (1997) 0.94
Concordance analysis of microbial genomes. Nucleic Acids Res (1998) 0.94
Staphylococcus haemolyticus contains two D-glutamic acid biosynthetic activities, a glutamate racemase and a D-amino acid transaminase. J Bacteriol (1995) 0.94
Protoporphyrin IX occurs naturally in colorectal cancers and their metastases. Cancer Res (2001) 0.93
Photosensitization of malignant tumors. Semin Surg Oncol (1986) 0.93
Differences in the resistant variants of Enterobacter cloacae selected by extended-spectrum cephalosporins. Antimicrob Agents Chemother (1996) 0.92
Photodynamic therapy in the management of resistant lower urinary tract carcinoma. Cancer (1987) 0.92
Time and sequence dependent influence of in vitro photodynamic therapy (PDT) survival by hyperthermia. Photochem Photobiol (1985) 0.92
Hematoporphyrin as a photosensitizer of tumors. Photochem Photobiol (1983) 0.92
The Escherichia coli Dga (MurI) protein shares biological activity and structural domains with the Pediococcus pentosaceus glutamate racemase. J Bacteriol (1994) 0.91
Hematoporphyrin derivative for detection and treatment of cancer. J Surg Oncol (1980) 0.90
Intracavitary photodynamic therapy for malignant pleural mesothelioma. Semin Surg Oncol (1995) 0.90
Operation and photodynamic therapy for pleural mesothelioma: 6-year follow-up. Ann Thorac Surg (1998) 0.89
Aspects of the cellular uptake and retention of hematoporphyrin derivative and their correlation with the biological response to PRT in vitro. Adv Exp Med Biol (1983) 0.89
Hyperthermic potentiation of photodynamic therapy employing Photofrin I and II: comparison of results using three animal tumor models. Lasers Surg Med (1987) 0.88
Fluorescence bronchoscopy for detection of lung cancer. Chest (1979) 0.88
Synthesis of beta-galactose-conjugated chlorins derived by enyne metathesis as galectin-specific photosensitizers for photodynamic therapy. J Org Chem (2001) 0.88
Porphyrin dimers as photosensitizers in photodynamic therapy. J Med Chem (1990) 0.88
An evaluation of photodynamic therapy in the management of cutaneous metastases of breast cancer. Eur J Cancer (1993) 0.87
A preliminary pharmacokinetic study of intravenous Photofrin in patients. J Clin Laser Med Surg (1996) 0.86
Whole bladder photodynamic therapy for transitional cell carcinoma of bladder. Urology (1985) 0.86
An assay for the quantitation of Photofrin in tissues and fluids. Photochem Photobiol (1997) 0.86
Photodynamic therapy. Adv Exp Med Biol (1985) 0.85
Alterations in peptidoglycan of Neisseria gonorrhoeae induced by sub-MICs of beta-lactam antibiotics. Antimicrob Agents Chemother (1987) 0.85
Characterization of intra-tumoral porphyrin following injection of hematoporphyrin derivative or its purified component. Photochem Photobiol (1987) 0.85
Photodynamic therapy for residual neoplasms of the perianal skin. Dis Colon Rectum (2000) 0.85
Haematoporphyrin derivative photosensitization and gamma-radiation damage interaction in Chinese hamster ovary fibroblasts. Int J Radiat Biol Relat Stud Phys Chem Med (1986) 0.84
The time course of cutaneous porphyrin photosensitization in the murine ear. Photochem Photobiol (1989) 0.84
Photoradiation therapy. Urology (1984) 0.83
Tobramycin uptake in Escherichia coli membrane vesicles. Antimicrob Agents Chemother (1995) 0.83
Fluorescence detection of tumors. Early diagnosis of microscopic lesions in preclinical studies. Cancer (1993) 0.83
Hematoporphyrin derivative in the diagnosis and treatment of lung cancer. Adv Exp Med Biol (1983) 0.82
Potentiation of photodynamic therapy by heat: effect of sequence and time interval between treatments in vivo. Lasers Surg Med (1985) 0.82
Photoradiation therapy--clinical and drug advances. Adv Exp Med Biol (1983) 0.82
The structure of the active component of hematoporphyrin derivative. Prog Clin Biol Res (1984) 0.81
Purpurinimides as photosensitizers: effect of the presence and position of the substituents in the in vivo photodynamic efficacy. Bioorg Med Chem Lett (2000) 0.81
Photodynamic therapy in gynecologic malignancies. Gynecol Oncol (1989) 0.81
Why are there no new antibiotics? Expert Opin Investig Drugs (1998) 0.81
Fast atom bombardment mass spectral analyses of Photofrin II and its synthetic analogs. Biomed Environ Mass Spectrom (1990) 0.80
UDP-N-acetylmuramyl-L-alanine functions as an activator in the regulation of the Escherichia coli glutamate racemase activity. Biochemistry (1995) 0.80
Comparative in vivo sensitizing efficacy of porphyrin and chlorin dimers joined with ester, ether, carbon-carbon or amide bonds. J Mol Recognit (1997) 0.80
Temperature rise during photoradiation therapy of malignant tumors. Med Phys (1983) 0.80
Protection of murine foot tissue and transplantable tumor against Photofrin-II-mediated photodynamic sensitization with WR-2721. J Photochem Photobiol B (1989) 0.79
Intra-abdominal applications of hematoporphyrin photoradiation therapy. Adv Exp Med Biol (1983) 0.79